{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-455339","form_type":"8-K","ticker":"XCUR","cik":"0001698530","company_name":"EXICURE, INC.","filed_at":"2026-11-10T20:50:16+00:00","discovered_at":"2026-11-10T20:51:00.494540+00:00","generated_at":"2026-11-10T20:51:04.430589+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Exicure to sell GPC-100 (burixafor) assets to Korea's GPCRT for KRW 6.5B (~US$4.8M)","bullets":["Aggregate cash price KRW 6.5B (~US$4.8M): KRW 500M deposit already paid and credited, KRW 2.0B due by November 16, 2026, KRW 4.0B at closing.","Assets: rights under the January 19, 2025 License and Collaboration Agreement with GPCR Therapeutics, plus IP, clinical/regulatory data, materials and equipment.","GPCRT assumes post-closing obligations including future milestone and royalty payments to GPCR, and bears GPC-100 program costs incurred on or after September 1, 2026.","GPC-100 was evaluated with propranolol for stem cell mobilization in multiple myeloma; GPCR USA completed its Phase 2 trial in January 2026.","Closing needs board approvals, regulatory and third-party consents, a GPCR waiver/release, and any required Exicure stockholder approval; timing not assured."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-455339","json":"https://secwatch.observer/filing/0001193125-26-455339.json","markdown":"https://secwatch.observer/filing/0001193125-26-455339.md","text":"https://secwatch.observer/filing/0001193125-26-455339.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1698530/000119312526455339/0001193125-26-455339-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1698530/000119312526455339/xcur-20261104.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-11-10T20:51:04.430589+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}